Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group, and Phase IV Study of Efficacy and Safety of Solifenacin Succinate in Patients With Overactive Bladder After TURP or PVP

NCT01747577 is registered in ClinicalTrials.gov with Astellas Pharma Korea, Inc. as lead sponsor.

NCT NCT01747577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01747577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel-group, and Phase IV Study of Efficacy and Safety of Solifenacin Succinate in Patients With Overactive Bladder After TURP or PVP
Lead sponsor
Astellas Pharma Korea, Inc.
Phase
Phase 4
Overall status
Completed
Start date
December 4, 2012
Completion date
October 24, 2013
Enrollment
68 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostate hyperplasia, overactive bladder, photoselective vaporization prostatectomy, transurethral resection of prostate